Compare Incyte Corporation (INCY) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs McCormick & Company, Incorporated — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while McCormick & Company, Incorporated trades at $44.81 (market cap $12.39B). The key difference: Incyte Corporation is the larger of the two by market cap, and McCormick & Company, Incorporated pays a 4.18% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and McCormick & Company, Incorporated for 67 Days on average.
| INCY | MKC | |
|---|---|---|
Market Cap | $22.85B | $12.39B |
Volume | 1,927,029 | 6,140,872 |
Sector | Health | Consumer Staples |
52-Week High | $129.93 | $71.65 |
52-Week Low | $83.80 | $44.14 |
Typical Hold Time | 33 Days | 67 Days |
Enterprise Value | $18.35B | $17.07B |
Dividend Yield | — | 4.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
MKC trades at $45.94, up 1.52% today, with a bearish technical signal despite recent earnings beats. The company reported strong Q3 2026 results with 17% sales growth and margin expansion, though net cash flow was negative $90.2M in 2025. Valuation metrics appear attractive with P/E of 8.31 and ROE of 23.37%, while analyst consensus is mixed with 33% buy ratings.
The stock offers value potential with a $53.50 price target upside, supported by dividend payments and operational strength. Key risks include integration challenges from recent acquisitions and macroeconomic pressure on consumer spending. The technical picture suggests near-term resistance at $46-$47 levels despite fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
